The solution improves the diagnosis and therapy by integrating proteomic analysis of blood-based biomarkers into Orchestrator for a more accurate prediction of lung nodule malignancy
Royal Philips has partnered with Biodesix to integrate the results of Biodesix’s Nodify Lung blood-based lung nodule risk assessment testing into the Philips Lung Cancer Orchestrator system.
The incorporation of proteomics data, along with the radiologic and patient history data currently used to determine treatment decisions, can help create diagnostic efficiency for cancer care centres in the management of lung nodule cases.
Philips developed the Lung Cancer Orchestrator solution to help health systems operationalise lung cancer screening and lung nodule management programmes at scale.
Clinicians may now categorise the risk of malignancy with the use of Biodesix’s Nodify Lung blood-based proteomic testing, which allows them to better direct resources to individuals who need them.
Philips Oncology Informatics and Genomics general manager Louis Culot said: “By incorporating Biodesix’s Nodify Lung testing, we take another step in leveraging integrated diagnostics from imaging, genomics, and now proteomic results from a simple blood draw to address key moments in the lung cancer patient journey, support care team decision-making, and help health systems learn from their practice patterns in a dashboard view.
“We expect the inclusion of Biodesix’s ground-breaking technology in Philips Lung Cancer Orchestrator to help drive more confident decisions for the care team, and ultimately benefit patients.”
The Philips Lung Cancer Orchestrator is an integrated patient management system for CT lung cancer screening programmes and incidental lung nodule findings.
It records patients’ names, appointments, diagnostic photos, test outcomes, and clinical judgments for each step of a patient’s screening and treatment journey for lung cancer.
The end-to-end patient journey is coordinated to create a fully traceable, fully documented timeline of scheduled actions, and data on tumour staging, radiology, pathology, and biomarker analyses for informed decision-making.
Royal Philips said that the ability to order and receive the results accelerates Biodesix’s proteomic testing directly to and from the Lung Cancer Orchestrator, adding new insights on nodule risk of malignancy.